BACKGROUND: Growth modulation index (GMI), the ratio of two times to progression measured in patients receiving two successive treatments (GMI = TTP2/TTP1), has been proposed as a criterion of phase II clinical trials. Nevertheless, its use has been limited until now. PATIENTS AND METHODS: We carried out a retrospective multicentre study in soft tissue sarcoma patients receiving a second-line treatment after doxorubicin-based regimens to evaluate the link between overall survival and GMI. Second-line treatments were classified as 'active' according to the EORTC-STBSG criteria (3-month progression-free rate >40% or 6-month PFR >14%). Comparisons used chi-squared and log-rank tests. RESULTS: The population consisted in 106 men and 121 women, 110 patients (48%) received 'active drugs'. Median OS from the second-line start was 317 days. Sixty-nine patients experienced GMI >1.33 (30.4%). Treatments with 'active drug' were not associated with OS improvement: 490 versus 407 days (P = 0.524). Median OS was highly correlated with GMI: 324, 302 and 710 days with GMI <1, GMI = [1.00-1.33], and GMI >1.33, respectively (P < 0.0001). In logistic regression analysis, the sole predictive factor was the number of doxorubicin-based chemotherapy cycles. CONCLUSION: GMI seems to be an interesting end point that provides additional information compared with classical criteria. GMI >1.33 is associated with significant OS improvement.
BACKGROUND: Growth modulation index (GMI), the ratio of two times to progression measured in patients receiving two successive treatments (GMI = TTP2/TTP1), has been proposed as a criterion of phase II clinical trials. Nevertheless, its use has been limited until now. PATIENTS AND METHODS: We carried out a retrospective multicentre study in soft tissue sarcomapatients receiving a second-line treatment after doxorubicin-based regimens to evaluate the link between overall survival and GMI. Second-line treatments were classified as 'active' according to the EORTC-STBSG criteria (3-month progression-free rate >40% or 6-month PFR >14%). Comparisons used chi-squared and log-rank tests. RESULTS: The population consisted in 106 men and 121 women, 110 patients (48%) received 'active drugs'. Median OS from the second-line start was 317 days. Sixty-nine patients experienced GMI >1.33 (30.4%). Treatments with 'active drug' were not associated with OS improvement: 490 versus 407 days (P = 0.524). Median OS was highly correlated with GMI: 324, 302 and 710 days with GMI <1, GMI = [1.00-1.33], and GMI >1.33, respectively (P < 0.0001). In logistic regression analysis, the sole predictive factor was the number of doxorubicin-based chemotherapy cycles. CONCLUSION:GMI seems to be an interesting end point that provides additional information compared with classical criteria. GMI >1.33 is associated with significant OS improvement.
Entities:
Keywords:
end point; growth modulation index; soft tissue sarcoma; time to progression
Authors: Mrinal M Gounder; Alona Zer; William D Tap; Samer Salah; Mark A Dickson; Abha A Gupta; Mary Louise Keohan; Herbert H Loong; Sandra P D'Angelo; Stephanie Baker; Mercedes Condy; Kjirsten Nyquist-Schultz; Lanier Tanner; Joseph P Erinjeri; Francis H Jasmine; Sharon Friedlander; Robert Carlson; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Joel Ellis; Michael Kauffman; Sharon Shacham; Gary K Schwartz; Albiruni Ryan Abdul Razak Journal: J Clin Oncol Date: 2016-07-25 Impact factor: 44.544
Authors: Thomas Brodowicz; Bernadette Liegl-Atzwager; Emmanuelle Tresch; Sophie Taieb; Andrew Kramar; Viktor Gruenwald; Marie Vanseymortier; Stéphanie Clisant; Jean-Yves Blay; Axel Le Cesne; Nicolas Penel Journal: BMC Cancer Date: 2015-03-14 Impact factor: 4.430
Authors: J Khalifa; M Ouali; L Chaltiel; S Le Guellec; A Le Cesne; J-Y Blay; P Cousin; L Chaigneau; E Bompas; S Piperno-Neumann; B Bui-Nguyen; M Rios; J-P Delord; N Penel; C Chevreau Journal: BMC Cancer Date: 2015-10-15 Impact factor: 4.430
Authors: Nadia Hindi; Irene Carrasco García; Alberto Sánchez-Camacho; Antonio Gutierrez; Javier Peinado; Inmaculada Rincón; Johanna Benedetti; Pilar Sancho; Paloma Santos; Paloma Sánchez-Bustos; David Marcilla; Victor Encinas; Sara Chacon; Cristobal Muñoz-Casares; David Moura; Javier Martin-Broto Journal: Cancers (Basel) Date: 2020-12-12 Impact factor: 6.639
Authors: Antoine Italiano; Shivani Nanda; Andrew Briggs; Jesus Garcia-Foncillas; Ulrik Lassen; Gilles Vassal; Shivaani Kummar; Cornelis M van Tilburg; David S Hong; Theodore W Laetsch; Karen Keating; John A Reeves; Marc Fellous; Barrett H Childs; Alexander Drilon; David M Hyman Journal: Cancers (Basel) Date: 2020-11-04 Impact factor: 6.639